

January 16, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of Investor Conference Call for Q3 & 9M FY26 with Senior Management of Mankind Pharma Limited (“the Company”)

Pursuant to Regulation 30 & 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will host Investor Conference Call on Tuesday, February 3, 2026 at 06:00 P.M. (IST) for Q3 & 9M FY26.

Details of the Investor Conference Call are enclosed herewith.

The same are also being uploaded on website of the Company at www.mankindpharma.com.

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a



Mankind Pharma Limited
Earnings Call Invite | Q3 & 9M FY26

You are cordially invited to the Earnings Call,
Scheduled on Tuesday, 03rd February 2026, at **06:00 PM IST**,
To discuss Q3 & 9M FY26 business performance and results:

The details of the earnings call are as below:

Earnings Call Details	
Date	Tuesday, 3 rd February 2026
Time	06:00 PM – 07:00 PM IST
Universal Dial-in	+91 22 6280 1102 +91 22 7115 8003
International Toll-Free Numbers	USA : 18667462133 UK : 08081011573 Singapore : 8001012045 Hong Kong : 800964448
Pre-register to avoid wait time	Click here to pre-register for the call and dial in directly without waiting for the operator.

Management will be represented by:

- Mr. Rajeev Juneja – Vice Chairman & Managing Director
- Mr. Sheetal Arora – Chief Executive Officer & Whole Time Director
- Mr. Arjun Juneja - Chief Operating Officer
- Mr. Sudipta Roy – Senior President – Sales & Marketing
- Mr. Ashutosh Dhawan – Global Chief Financial Officer
- Mr. Prakash Agarwal – President (Strategy)
- Mr. Abhishek Agarwal – Head - Investor Relations & AVP - Strategy

For details, please contact:

Mankind Pharma Limited Abhishek Agarwal E: Investor.relations@mankindpharma.com , T: 011 – 46846700	Adfactors PR Snighter Albuquerque / Smit Shah E: Snighter.albuquerque@adfactorspr.com / smit.shah@adfactorspr.com , M: +91 9870789596
---	---